Forthyron 600 Microgram Flavoured Tablet

Main information

  • Trade name:
  • Forthyron 600 Microgram Flavoured Tablet
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Forthyron 600 Microgram Flavoured Tablet
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • levothyroxine sodium
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0388/003
  • Authorization date:
  • 26-10-2011
  • EU code:
  • UK/V/0388/003
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:December2011

AN:01149/2010

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Forthyronflavoured600microgramtabletsfordogs

UK:Thyforonflavoured600microgramtabletsfordogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Onetabletcontains:

600microgramlevothyroxinesodiumpertabletequivalentto583microgram

levothyroxine

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

Tablet

Offwhiteroundtabletwithbrownspots,quadrisectwithsidescores

Thetabletsmaybedividedintohalvesorquarters

4. CLINICALPARTICULARS

4.1. Targetspecies

Dogs.

4.2. Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofhypothyroidismindogs.

4.3. Contra-indications

Donotuseindogssufferingfromuncorrectedadrenalinsufficiency.

Donotuseincasesofknownhypersensitivitytolevothyroxinesodium.

4.4. Specialwarningsforeachtargetspecies

Thediagnosishypothyroidismshouldbeconfirmedwithappropriatetests.

4.5. Specialprecautionsforuse

Specialprecautionsforuseinanimals

Asuddenincreaseindemandforoxygendeliverytoperipheraltissues,plusthe

chronotropiceffectsoflevothyroxinesodium,mayplaceunduestressonapoorly

functioningheart,causingdecompensationandsignsofcongestiveheartfailure.

Hypothyroiddogssufferingfromhypoadrenocorticismhaveadecreasedabilityto

metaboliselevothyroxinesodiumandthereforeanincreasedriskofthyrotoxicosis.

Dogswithconcurrenthypoadrenocorticismandhypothyroidismshouldbestabilised

withglucocorticoidandmineralocorticoidtreatmentpriortotreatmentwithlevothyroxine

sodiumtoavoidprecipitatingahypoadrenocorticalcrisis.Afterthis,thyroidtests

shouldberepeated,thengradualintroductionoflevothyroxinetherapy,startingwith25%

Revised:December2011

AN:01149/2010

Page2of6

ofthenormaldose,increasingby25%incrementseveryfortnightuntiloptimal

stabilisationisachievedisrecommended.Gradualintroductionoftherapyisalso

recommendedfordogswithotherconcurrentillnesses;particularlyindogswithcardiac

disease,diabetesmellitusandrenalorhepaticdysfunction.

Specialprecautionstobetakenbythepersonadministeringthemedicinal

producttoanimals

Washhandsafteradministeringthetablets.Pregnantwomenshouldhandletheproduct

withcaution.Inthecaseofaccidentalingestion,seekmedicaladviceimmediatelyand

showthepackageleafletorthelabeltothephysician.Note:thisproductcontainsahigh

concentrationofL-thyroxinesodiumandmaypresentarisktohumans,inparticular

children,ifingested.

4.6. Adversereactions(frequencyandseriousness)

Restorationofphysicalactivitymayunmaskorintensifyotherproblems,suchas

osteoarthrosis.Adversereactionsofthyroidhormonesaregenerallyassociatedwith

excessivedosageandcorrespondtothesymptomsofhyperthyroidism.Seealso

section4.10.

4.7. Useduringpregnancy,lactationorlay

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedinpregnantor

lactatingbitches.However,levothyroxineisanendogenoussubstanceandthyroid

hormonesareessentialforthedevelopingfoetus,especiallyduringthefirstperiodof

gestation.Hypothyroidismduringpregnancymayresultinmajorcomplicationssuchas

foetaldeathandapoorperinataloutcome.Maintenancedoseoflevothyroxinesodium

mayneedadjustmentduringpregnancy.Pregnantbitchesshouldthereforebe

monitoredonaregularbasefromconceptionuntilseveralweeksafterdelivery.

4.8.Interactionswithothermedicinalproductsandotherformsofinteraction

Avarietyofdrugsmayimpairplasmaortissuebindingofthethyroidhormonesoralter

thyroidhormonemetabolism(eg.barbiturates,antacids,anabolicsteroids,diazepam,

furosemide,mitotane,phenylbutazone,phenytoin,propranolol,largedosesof

salicylates,andsulphonamides.).Whentreatingdogsthatarereceivingconcurrent

medicationthepropertiesofthesedrugsshouldbetakenintoconsideration.

Estrogensmayincreasethyroidrequirements.

Ketaminemaycausetachycardiaandhypertensionwhenusedinpatientsreceiving

thyroidhormones.Theeffectofcatecholaminesandsympaticomimeticsisincreasedby

levothyroxine.

Anincreaseinthedosageofdigitalismaybenecessaryinapatientthathadpreviously

compensatedcongestiveheartfailureandthatisplacedonthyroidhormone

supplementation.Followingtreatmentofhypothyroidismindogswithconcurrent

diabetes,carefulmonitoringofdiabeticcontrolisrecommended.

Mostdogsonchronichigh-dose,dailyglucocorticoidtherapywillhaveverylowor

Revised:December2011

AN:01149/2010

Page3of6

undetectableserumT

concentrations,aswellassubnormalT

values.

4.9 Amountstobeadministeredandadministrationroute

Therecommendedstartingdosageoflevothyroxinesodiumis10µg/kgbodyweight

orallyevery12hour.Becauseofvariabilityinabsorptionandmetabolism,thedosage

mayrequirealterationsbeforeacompleteclinicalresponseisobserved.Theinitial

dosageandfrequencyofadministrationaremerelyastartingpoint.Therapyhastobe

highlyindividualisedandtailoredtotherequirementsoftheindividualdog.When

initiatingdosingofdogsweighinglessthan5kgbodyweight,aquarterofone200μg

tabletshouldbeadministeredoncedaily.Suchcases

shouldbemonitoredcarefully.Inthedog,absorptionoflevothyroxinesodiummaybe

affectedbythepresenceoffood.Thetimingoftreatmentanditsrelationtofeeding

shouldthereforebekeptconsistentfromdaytoday.Toadequatelymonitortherapy,

troughvalues(justpriortotreatment)andpeakvalues(aboutthreehoursafterdosing)

ofplasmaT

canbemeasured.Inadequatelydoseddogspeakplasmaconcentration

ofT

shouldbeinthehigh-normalrange(approximately30to47nmol/l)andtrough

valuesshouldbeaboveapproximately19nmol/l.IfT

levelsareoutsidethisrangethe

levothyroxinedosecanbeadjustedin50to200µgincrementsuntilthepatientis

clinicallyeuthyroidandserumT

iswithinthereferencerange.PlasmaT

levelscanbe

retestedtwoweeksafterchangeofdosage,butclinicalimprovementisanequally

importantfactorindeterminingindividualdosageandthiswilltakefourtoeightweeks.

Whentheoptimumreplacementdosehasbeenattained,clinicalandbiochemical

monitoringmaybeperformedevery6 –12months.

Tobreakatabletaccuratelyandeasily,placethetabletscoreside

upandapplypressurewithyourthumb.

Tobreakthetabletintwoparts;holdonehalfofthetabletdownandpressdownthe

otherhalf.

4.10.Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Followingadministrationofoverdosesthyrotoxicosiscouldoccur.Thyrotoxicosisasa

sideeffectofmildoversupplementationisuncommonindogs,owingtothecanine

abilitytocatabolizeandexcretethyroidhormones.Incaseofaccidentalintakeoflarge

amountsoftheveterinarymedicinalproductabsorptioncanbedecreasedbyinduction

ofvomitingandoraladministrationofbothactivatedcharcoalandmagnesiumsulphate

once.

Overdosesofthreeuptosixtimeslabelrecommendedstartingdosefor4consecutive

weeksinhealthy,euthyroiddogsresultedinnosignificantclinicalsignsthatcouldbe

attributedtotreatment.Singleoverdoseupto3-6xtherecommendeddosedoesnot

poseathreattothedog,andnoactionsarenecessary.However,followingchronic

Revised:December2011

AN:01149/2010

Page4of6

over-supplementation,clinicalsignsofhyperthyroidismsuchaspolydipsia,polyuria,

panting,weightlosswithoutanorexia,andeitherorbothtachycardiaandnervousness

maytheoreticallyoccur.ThepresenceofthesesignsshouldresultinevaluationofT

serumconcentrationstoconfirmthediagnosis,andimmediatediscontinuanceofthe

supplementation.Oncethesignshaveabated(daystoweeks),thethyroiddosagehas

beenreviewed,andtheanimalhasfullyrecovered,alowerdosagemaybeinstituted,

withtheanimalbeingmonitoredclosely.

4.11.Withdrawalperiods

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:syntheticthyroidhormones

ATCvetcode:QH03AA01.

5.1. Pharmacodynamicproperties

Pharmacologicallylevothyroxineisclassifiedasahormonalpreparationthatreplaces

deficientendogenoushormones.

LevothyroxineT

isconvertedtotriiodothyronineT

actsoncellularprocessesvia

specificligand-receptorinteractionswiththenucleus,themitochondria,andtheplasma

membrane.InteractionofT

withbindingsitesleadstoaugmentedtranscriptionofDNA

ormodulationofRNA,thusinfluencingproteinsynthesisandenzymeaction.

Thyroidhormonesactonmanydifferentcellularprocesses.Indevelopinganimalsand

humanbeings,theyarecrucialdeterminantsofnormaldevelopment,especiallyinthe

centralnervoussystem.Thyroidsupplementationincreasesbasalcellularmetabolism

andoxygenconsumptiontherebyaffectingthefunctionofvirtuallyallorgansystems.

5.2. Pharmacokineticparticulars

SomedogsappearedtoconsistentlyeitherabsorbL-thyroxinebetterand/oreliminateit

moreslowlythandootherdogs.Furthermoreabsorptionandeliminationrateis

influencedbydailyintakeoflevothyroxinesodium(highabsorption/loweliminationin

caseoflowintakeandviceversaincaseofhighintake).Thevariabilityin

pharmacokineticparametersbetweenindividualdogsisconsiderableand,althoughthe

presenceoffoodmayaffectabsorption,itisconsideredtohaveaminoreffectonthe

parametersoverall.Absorptionisrelativelyslowandincomplete:InmostcasesT

occursbetween1to5hoursafteroraladministration,meanC

variesmorethan3

foldbetweendogsonthesamedoses.Inadequatelydoseddogstheplasmapeak

approachesorslightlyexceedstheupperlimitofnormalplasmaT

levels,andbythe

endof12hoursafteroraladministration,plasmaT

usuallydeclinestothelowerhalfof

thenormalrange.TheratesofdisappearanceofT

fromtheplasmaareslowedin

hypothyroidism.Alargepartofthethyroxineistakenupbytheliver.L-thyroxineisbound

toplasma-proteinsandplasmalipoproteins.Partofadoseofthyroxineismetabolised

Revised:December2011

AN:01149/2010

Page5of6

tothemorepotenttriiodothyronine(T

)bydeiodination.Theprocessofdeiodination

continues.Thesefurtherdeiodinatedmetabolicproducts(otherthanT

andT

)donot

havethyromimeticactivity.Otherpathwaysofthyroidhormonemetabolisminclude

conjugationtoformsolubleglucuronidesandsulphatesforbiliaryorurinaryexcretionas

wellascleavageoftheetherlinkageoftheiodothyroninemolecule.Inthedog,over

50%oftheT

producedeachdayarelostinthefaeces.Theextrathyroidalbodystores

ofT

areeliminatedandreplacedinabout1day.

6. PHARMACEUTICALPARTICULARS

6.1. Listofexcipients

Calciumhydrogenphosphatedihydrate,

Cellulose,Microrcrystalline,

SodiumStarchGlycolate(typeA),

Magnesiumstearate.

Naturalmeatflavour

6.2. Incompatibilities

Notapplicable

6.3. Shelf-life

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelf-lifeofremainingtabletparts:4days.

6.4. Specialprecautionsforstorage

Donotstoreabove25°C.

Returnanydividedtablettotheopenedblisterandusewithin4days.

6.5. Natureandcontentsofimmediatepackaging

Theproductispackagedinablister[Aluminium(20µm)-PVC/PE/PVDC(250/30/90)

white].

10Tabletsperblister,5or25blisterspercarton,50or250tabletspercarton.

Notallpacksizesmaybemarketed.

6.6. Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerials,derivedfromtheuseofsuchproductsif

appropriate.

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

EurovetAnimalHealthB.V.

Revised:December2011

AN:01149/2010

Page6of6

Handelsweg25,5531AEBladel

TheNetherlands

8. MARKETINGAUTHORIZATIONNUMBER

Vm16849/4036

9. DATEOFFIRSTAUTHORISATION

22November2011

10. DATEOFREVISIONOFTHETEXT

December2011

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

31-8-2018

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA is warning the public about a voluntary recall of one lot of montelukast sodium tablets made by Camber Pharmaceuticals due to incorrect drug in bottles

FDA - U.S. Food and Drug Administration

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

15-3-2018

Duro-K 600 mg potassium chloride tablets

Duro-K 600 mg potassium chloride tablets

Advisory – lead content may exceed regulatory guidelines

Therapeutic Goods Administration - Australia

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

24-8-2018

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

#OnePairTakeCare https://twitter.com/CDCgov/status/1032656962389913600 …

FDA - U.S. Food and Drug Administration